Roughly one in 14 people with lower-risk myelodysplastic syndromes (LR-MDS) have an infection in the first year after ...

During a live event, Chris Benton, MD, discussed the focus on anemia management, reducing transfusions, and improving quality ...

The nature of immune dysregulation is markedly different between various MDS risk groups. In low-risk MDS, the immune system is in a proinflammatory state, whereas in high-risk disease ...

real-world registry enrolling adult patients diagnosed with lower-risk MDS—defined as International Prognostic Scoring System low or intermediate-1—in 16 European countries and Israel.

Myelodysplastic syndromes (MDS) include a group of hematopoietic malignancies characterized by dysplastic changes, ineffective hematopoiesis and variable risk of leukemic progression. At diagnosis ...

Rytelo is approved for low-risk MDS patients with transfusion-dependent anemia, excluding those with isolated deletion 5q. Phase 3 IMerge trial data demonstrated significant reduction in red blood ...

The biotech has launched a strategic review to consider options, including a possible sale, following shareholder pressure.

for diagnosing myelodysplastic syndrome (MDS), including in low-risk patients. A new validation study affirms the value of flow cytometry to diagnose myelodysplastic neoplasms in cytopenic patients.

low or intermediate risk myelodysplastic syndromes (lower-risk MDS or LR-MDS) without an isolated deletion 5q cytogenetic (non-del 5q) abnormality and who had an unsatisfactory response to or are ...

Bexmarilimab and Vidaza achieved high response rates in higher-risk myelodysplastic syndrome, meeting the phase 2 BEXMAB trial's primary endpoint. The treatment demonstrated a 63% objective response ...